Results 241 to 250 of about 538,057 (302)

Leveraging Dissolved Organic Matter Collections as a Natural Chemical Library to Link Molecular Traits with Cellular Morphological Responses. [PDF]

Environ Sci Technol
Zhang X, Harir M, Schick J, Lucio M, Perdue EM, Schmitt-Kopplin P.   +5 more
europepmc   +1 more source

Fas-induced Apoptosis.

Internal Medicine, 1998
openaire   +3 more sources

Real‐World, Prospective, Multicenter Outcomes to Brodalumab Treatment in Patients With Moderate‐to‐Severe Psoriasis in Greece (The RESOLVE Study)

JEADV Clinical Practice, EarlyView.
RESOLVE was a prospective, real‐world study in patients with moderate‐to‐severe psoriasis treated with brodalumab. At Week 12, 76.4% achieved PASI ≤ 3, 53.5% PASI100, and 71.5%/54.2% achieved sPGA0/1 and sPGA 0, respectively. At Week 52, 96.1% achieved sPGA success (clear/almost clear). Furthermore, at Week 52, mean DLQI scores decreased by 12.6 ± 6.2,
Electra Nicolaidou, Pantelis Panagakis, Dimitrios Xekardakis, Natalia Rompoti, Marina Papoutsaki, Ioanna Lefaki, Kanella Kalapothakou, Despina Exadactylou, Athanasios Chaniotis, Vasiliki Chasapi, Alexander Stratigos   +10 more
wiley   +1 more source

Evaluating the Combined Effects of an Adverse Childhood Experiences-Focused Family Advocate Model and the Strengthening Families Program: Study Protocol for a Hybrid Type 1 Effectiveness-Implementation Trial in 36 New Jersey Communities.

JMIR Res Protoc
Elgin D, Graham PW, Johnson K, Khan S, Mills M, Wondimagegnehu F, Gibbons B, Williams J, Jiang X, Zapcic A, Simon B.   +10 more
europepmc   +1 more source

Gustatory avoidance of fatty acids by <i>Aedes aegypti</i> depends on an arthropod-specific TRP channel. [PDF]

Proc Natl Acad Sci U S A
Dhakal S, Bontempo AE, Singh R, Dhavan P, Montell C.   +4 more
europepmc   +1 more source

Clinically Meaningful Improvements in Quality of Life, Including Sleep, With Two‐Week and Monthly Dosed Rademikibart: A Phase 2 Randomized Trial in Adults With Moderate‐to‐Severe Atopic Dermatitis

JEADV Clinical Practice, EarlyView.
Rademikibart, a potent IL‐4Rα‐targeting antibody, achieved its primary endpoint as a treatment for adults with moderate‐to‐severe atopic dermatitis (AD) in the CBP‐201‐WW001 Phase 2 trial. There is a need for AD treatment options with convenient dosing intervals.
Jonathan I. Silverberg, Emma Guttman‐Yassky, Raúl Collazo   +2 more
wiley   +1 more source

Detailed composition of wax esters in mouse sebum and the involvement of FAR2 and AWAT2. [PDF]

iScience
Kuribayashi K, Jojima K, Yamamoto M, Takeda M, Kihara A.   +4 more
europepmc   +1 more source

Negative Energy Balance in Transition Cows Induces Complex Changes in Lipid Profile of Milk. [PDF]

Metabolites
Liu Z, Ezernieks V, Hemsworth JE, Reich CM, Bath CR, Berkhout MJ, Tahir MS, Marett LC, Chamberlain AJ, Goddard ME, Xiang R, Rochfort SJ.   +11 more
europepmc   +1 more source

Raman Spectroscopy-Based Quantitative Analysis of Fatty Acid Compositions of Lipid Droplets in Live Cells. [PDF]

Anal Chem
Paramitha PN, Iwasaki K, Andriana BB, Otoki Y, Kusumoto I, Ozaki Y, Nakagawa K, Sato H.   +7 more
europepmc   +1 more source